We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+11.82%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$328M
AUM Growth
+$81.1M
(+33%)
Cap. Flow
+$76.2M
Cap. Flow
% of AUM
23.2%
Top 10 Holdings %
Top 10 Hldgs %
53.81%
Holding
97
New
24
Increased
8
Reduced
15
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$32.7M |
| 2 |
Abbott
ABT
|
+$18.5M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$17.3M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
+$13.9M |
| 5 |
ARK Innovation ETF
ARKK
|
+$13.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$12.1M |
| 2 |
West Pharmaceutical
WST
|
+$8.84M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$8.36M |
| 4 |
Celldex Therapeutics
CLDX
|
+$7.85M |
| 5 |
Stevanato
STVN
|
+$6.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.57% |
| 2 | Energy | 0.07% |
| 3 | Real Estate | 0.03% |
| 4 | Materials | 0.02% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$70.9B
| $35.7M | 10.86% |
+43,389
| New | +$32.7M |
|
|
2
West Pharmaceutical
WST
$25.3B
| $23.2M | 7.05% |
66,830
-30,254
| -31% | -$8.84M |
|
|
3
Abbott
ABT
$175B
| $17.7M | 5.39% |
+174,802
| New | +$18.5M |
|
|
4
Tandem Diabetes Care
TNDM
$1.17B
| $17M | 5.16% |
+417,448
| New | +$17.3M |
|
5
Eli Lilly
LLY
$1.05T
| $15.3M | 4.65% |
44,448
-10,021
| -18% | -$3.38M |
|
|
CTLT
6
DELISTED
CATALENT, INC.
CTLT
| $14.8M | 4.51% |
+225,399
| New | +$13.9M |
|
7
Illumina
ILMN
$28.2B
| $14.6M | 4.45% |
+64,578
| New | +$13.2M |
|
|
8
ARK Innovation ETF
ARKK
$6.15B
| $14.1M | 4.3% |
+350,000
| New | +$13.4M |
|
9
Sarepta Therapeutics
SRPT
$1.82B
| $12.3M | 3.73% |
88,961
-30,734
| -26% | -$3.99M |
|
|
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
| $12.2M | 3.7% |
1,327,097
+642,541
| +94% | +$5.28M |
|
11
Merck
MRK
$315B
| $12.2M | 3.7% |
114,242
-12,670
| -10% | -$1.37M |
|
12
Axsome Therapeutics
AXSM
$11.8B
| $9.2M | 2.8% |
149,205
-50,849
| -25% | -$3.34M |
|
13
Thermo Fisher Scientific
TMO
$198B
| $9.16M | 2.79% |
+15,889
| New | +$8.96M |
|
14
Teva Pharmaceuticals
TEVA
$37.3B
| $8.96M | 2.73% |
+1,012,373
| New | +$10M |
|
15
Evolent Health
EVH
$654M
| $8.7M | 2.65% |
+268,011
| New | +$8.48M |
|
16
Xenon Pharmaceuticals
XENE
$6.6B
| $7.94M | 2.42% |
221,730
+128,366
| +137% | +$4.74M |
|
17
AbbVie
ABBV
$450B
| $7.84M | 2.39% |
+49,213
| New | +$7.52M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.5B
| $7.4M | 2.25% |
76,070
-48,909
| -39% | -$5.07M |
|
|
19
Stevanato
STVN
$5.23B
| $7.19M | 2.19% |
277,467
-296,570
| -52% | -$6.36M |
|
|
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.11M | 1.86% |
67,206
-74,260
| -52% | -$4.36M |
|
21
Guardant Health
GH
$20.7B
| $5.98M | 1.82% |
255,011
+124,563
| +95% | +$3.56M |
|
|
VTYX
22
DELISTED
Ventyx Biosciences
VTYX
| $5.12M | 1.56% |
+152,842
| New | +$5.94M |
|
|
APLS
23
DELISTED
Apellis Pharmaceuticals
APLS
| $5.08M | 1.55% |
77,048
-144,849
| -65% | -$8.36M |
|
24
uniQure
QURE
$2.77B
| $4.58M | 1.39% |
+227,273
| New | +$4.77M |
|
25
Inspire Medical Systems
INSP
$1.46B
| $4.1M | 1.25% |
+17,523
| New | +$4.43M |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q1 2023 Portfolio in Review
As of Q1 2023, Tri Locum Partners held 97 positions worth $328M, up 33% from $247M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Tri Locum Partners deployed $76.2M of net new capital in Q1 2023, opening 24 new positions and adding to 8 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 43,389 shares worth $35.7M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 91% a quarter earlier, followed by Energy and Real Estate.
On the sell side, the largest reduction was West Pharmaceutical, an estimated $8.84M trimmed.
- Tri Locum Partners's largest Q1 2023 buy was Regeneron Pharmaceuticals: 43,389 shares worth $35.7M.
- Tri Locum Partners added most to Praxis Precision Medicines in Q1 2023, an estimated $6.93M increase.
- Tri Locum Partners's biggest Q1 2023 reduction was West Pharmaceutical, cutting an estimated $8.84M.
- Tri Locum Partners fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $12.1M.
- Tri Locum Partners's ten largest holdings make up 54% of its $328M portfolio in Q1 2023.
- Tri Locum Partners opened 24 new positions and closed 50 in Q1 2023.
- Tri Locum Partners's portfolio value rose 33% quarter-over-quarter to $328M.
Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.